Since the first derivations of embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC), there has been impressive progress toward understanding their biology and developing safe clinical applications. In moving toward more robust clinical use of pluripotent cells, many parameters should be carefully considered, including the logistics of manufacturing and supply chain, purity, potency assays and karyotypic stability.